Our extensive network ensures you’ll be able to bridge the translational gap, no matter the area.

Our partner services

In vitro assays

  • Cytotoxicity (e.g. MTT, Trypan Blue)

  • Genotoxicity (e.g., MNT, Comet assay)

  • Apoptosis assays (e.g., Annexin V, TUNEL assays)

  • Mitochondrial toxicity

  • AMES testing

  • Customized assay development

In vivo assays

  • Toxicity testing (OECD 402, 411, 407, 408, 425)

  • Behavioural testing (e.g., T-maze, Morris Water Maze)

  • Motor function (Rotarod, Grip test)

  • Cognitive assessment (Touch screen, FOB, Operant testing)

  • In vivo efficacy and testing studies (ADME, PKPD)

  • Carcinogenicity studies

  • Animal Models (Transgenic, Inbred, Outbred, Syngeneic, Xenografted)

  • Customized animal studies

Bioanalytical

  • Metabolomics

  • ELISA

  • PCR

  • Western blotting

  • Flow cytometry

  • Next Generation Sequencing (NGS)

  • LC-MS/GC-MS

Contact Us

Ex vivo

  • Histopathological assessment (DAB, fluorescence)

  • Organ tissue sample collection

  • Immune profiling of tissue samples (cytokines, immune cells)

  • Slice-based electrophysiology

Consultation

  • Experimental Design

  • Risk management strategies

  • Project Management

  • Protocol Development

  • Quality Management Systems

Analysis

  • Statistical modelling (Linear modelling, ANOVA, etc.)

  • Pharmacokinetic parameter estimations (Cmax, terminal half-life, NCA, AUC)

Miscellanous

  • Biomanufacturing optimization (CDM optimization)

  • Antibody production (mABs, ADCs, BITEs, etc.)

  • Peptide manufacturing

  • Equipment Procurement

Workflow

Flowchart of Preclinical Research Program process, starting from Preclinical Research Program at the top, moving through Consultation, Review and Edits, Study Design and Experiment, Study Report, Study Proposal, Experimental Data, and ending with Partner Labs at the bottom. The Vivogenia logo, which includes a DNA strand, a microscope, and the company name, is displayed on the right side of the flowchart.

We provide a seamless, full-service partnership to advance your preclinical research. Our proven workflow manages every step, from initial strategy to final report, ensuring quality.

We discuss your preclinical research needs during consultation and formulate a study proposal containing all the necessary experiments to be carried out.

The experiments are executed in confidentiality by vetted partner labs, with constant oversight by us, ensuring the project stays on track.

Once we obtain the experimental data, we perform and advise on analyses, compiling the final report for your review.

We provide long-term technical and scientific support for your projects, even after it has ended.

Scenario 1

Company T is developing a new immunotherapy against pancreatic cancer, and has just established proof-of-concept efficacy in vitro for their immunotherapy. Company T consults with Vivogenia on next steps for bringing their therapy forward. From the consultation, Vivogenia determines that Company T would like to perform a pharmacokinetic study to evaluate the persistence and biodistribution of their particular immunotherapy.

Study Design

Animal model: NSG Immunodeficient mice, 6-8 weeks old
Dosing regime: Single injection, intravenous, 3 doses
Number of animals: 6 per dose

Study Details

  1. Weekly sampling of blood based on predicted half life of similar class of therapeutic.

  2. Weighing of animals for adverse immunotoxic effects from the doses.

  3. Evaluation of the presence of test article (TA) in blood at different doses to assess
    PK non-linearity.

  4. ELISA-based approach to the quantification of terminal half-life, AUC, Cmax and other
    metrics of the test article.

Study Deliverables

  1. PK data containing terminal half life, AUC, Cmax, Tmax derived from ELISA-based assay

  2. Evaluation of non-linearity based on elimination rate

  3. Report containing the details of the experiments.

A timeline chart for NSG immunodeficient mice aged 6-8 weeks showing weekly procedures. On days 0, 7, 14, and 21, mice are weighed and blood is collected. On day 7, 14, 21, and 28, mice receive TA administration. The chart includes legends for weighing, TA administration, and blood collection, and notes three groups with six mice each.

Scenario 2

Company B is planning to register their health supplement product for regulatory approval in Australia. Company B consults with Vivogenia on the experimental data requirements needed to demonstrate their product is safe and efficacious. Vivogenia proposes cytotoxicity, genotoxicity testing for Company B, based on OECD guidelines for safety. Vivogenia also proposes in vivo bioavailability testing using mice models to understand the biodistribution of this product.

Study Design

Animal model: NSG Immunodeficient mice, 6-8 weeks old
Dosing regime: Single injection, intravenous, 3 doses
Number of animals: 6 per dose

Study Details

  1. Weekly sampling of blood based on predicted half life of similar class of therapeutic.

  2. Weighing of animals for adverse immunotoxic effects from the doses.

  3. Evaluation of the presence of test article (TA) in blood at different doses to assess
    PK non-linearity.

  4. ELISA-based approach to the quantification of terminal half-life, AUC, Cmax and other
    metrics of the test article.

Book a consultation